Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 11,49€(+9,32%). Der Median liegt bei 11,49€(+9,32%).
Kaufen | 5 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients
Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI Congress ; Click here to register There are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management including total parenteral nutrition (TPN) - which carries the risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay This proof-of-concept data in MVID supports crofelemer's potential inclusion in the European Medicines Agency's (EMA) PRIME program for expediated and assisted regulatory approval in the EU as well as FDA's Breakthrough Therapies program for expedited regulatory approval in the US SAN FRANCISCO, CA / ACCESS Newswire / April 30, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required TPN and/or supplementary intravenous fluids, collectively referred to as parenteral support (PS) in patients with intestinal failure due to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) by up to 27% and 12.5% respectively. In addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output - an indicator of improved nutrient oral absorption.» Mehr auf accessnewswire.com
REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF)
The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management This data was presented at the Annual ELITE PED-GI Congress by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology and the primary investigator for this study SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today issued a reminder that Jaguar is hosting an investor webcast on Wednesday, April 30, 2025 at 8:30 AM Eastern to review the initial results of the proof-of-concept investigator-initiated trial of a novel liquid formulation of crofelemer, Jaguar's plant-based anti-secretory prescription drug, in patients with the rare diseases microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF) that were presented by Dr. Mohamad Miqdady on April 26, 2025 at the 11th Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates. Participation Instructions for Jaguar Investor Webcast When: Wednesday, April 30, 2025 at 8:30 AM Eastern Time Where: Online Registration link for conference: Click Here About Crofelemer Crofelemer is a novel, oral plant-based prescription medicine purified from the red bark sap, also referred to as "dragon's blood," of the Croton lechleri tree in the Amazon Rainforest.» Mehr auf accessnewswire.com
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress
Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's PRIME program for novel medicines targeting unmet medical needs and the FDA's Breakthrough Therapies program SAN FRANCISCO, CA / ACCESS Newswire / April 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics today announced that preliminary results from the ongoing pediatric investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for various congenital diarrheal disorders (CDD), including MVID and SBS with intestinal failure (SBS-IF), will be presented by Dr. Mohamad Miqdady at the April 24-26, 2025 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates. MVID and SBS-IF, rare orphan diseases requiring intensive parenteral nutrition and support, have severe morbidity and mortality implications and impact the quality of life of both patients and their caregivers.» Mehr auf accessnewswire.com
Unternehmenszahlen
(EUR) | Dez. 2024 | |
---|---|---|
Umsatz | 3,37 Mio | 62,08% |
Bruttoeinkommen | 2,84 Mio | 206,86% |
Nettoeinkommen | −9,53 Mio | 14,92% |
EBITDA | −15,14 Mio | 97,58% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 7,08 Mio€ |
Anzahl Aktien | 674,01k |
52 Wochen-Hoch/Tief | 478,11€ - 3,56€ |
Dividenden | Nein |
Beta | 1,12 |
KGV (PE Ratio) | −0,09 |
KGWV (PEG Ratio) | −0,01 |
KBV (PB Ratio) | 0,48 |
KUV (PS Ratio) | 0,68 |
Unternehmensprofil
Jaguar Health, Inc. ist ein kommerzielles Pharmaunternehmen, das sich auf die Entwicklung von verschreibungspflichtigen Medikamenten für Menschen und Tiere mit Magen-Darm-Beschwerden, insbesondere chronischer und schwächender Diarrhöe, konzentriert. Das Unternehmen ist in zwei Segmenten tätig: Human Health und Animal Health. Es vermarktet Mytesi für die symptomatische Linderung von nicht-infektiösem Durchfall bei Erwachsenen mit HIV/AIDS unter antiretroviraler Therapie. Das Unternehmen entwickelt außerdem Crofelemer für mehrere mögliche Folgeindikationen, darunter krebstherapiebedingte Diarrhöe; Orphan-Drug-Indikationen zur symptomatischen Linderung von Diarrhöe bei Säuglingen und Kindern mit angeborenen Durchfallerkrankungen und bei erwachsenen und pädiatrischen Patienten mit Kurzdarmsyndrom mit Darminsuffizienz; unterstützende Behandlung zur Linderung von Diarrhöe bei entzündlichen Darmerkrankungen; durchfalldominantes Reizdarmsyndrom; und für idiopathische/funktionelle Diarrhöe. Darüber hinaus entwickelt das Unternehmen Lechlemer, ein sekretionshemmendes Mittel der zweiten Generation gegen Cholera, und Canalevia, einen oralen Arzneimittelkandidaten auf pflanzlicher Basis zur Behandlung von Chemotherapie-induzierter Diarrhö bei Hunden und von trainingsinduzierter Diarrhö bei Hunden. Jaguar Health, Inc. wurde 2013 gegründet und hat seinen Hauptsitz in San Francisco, Kalifornien.
Name | Jaguar Health |
CEO | Lisa A. Conte |
Sitz | San Francisco, ca USA |
Website | |
Industrie | Chemikalien |
Börsengang | |
Mitarbeiter | 49 |
Ticker Symbole
Börse | Symbol |
---|---|
NASDAQ | JAGX |
Düsseldorf | 1JA.DU |
Frankfurt | 1JA.F |
München | 1JA.MU |
Assets entdecken
Shareholder von Jaguar Health investieren auch in folgende Assets